C5AR1 and granulomatosis with polyangiitis: The ADVOCATE trial is the first phase 3 RCT to investigate the safety and efficacy of avacopan (a novel complement 5a receptor 1 [C5aR1] antagonist) as adjunctive therapy to RTX or CYC in patients with GPA/MPA and reduced or no GC exposure [22].